Gilead Sciences stock
GILDNASDAQGilead Sciences, Inc., HealthcareISIN US3755581036
58Score 58 out of 100, Neutral
Price and trend
86 / 100
Price history
+38% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 20% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 66).
The price is 2.7% below its 52-week high. Largest decline in 20 years: 54% (June 2015 to December 2020).
Chart figures for advanced users
- SMA 50$154.40
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$141.44
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)66
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$118.30
- The lowest closing price of the last twelve months.
- Resistance$174.48
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Gilead Sciences, Inc. belongs to the Drug Manufacturers (General) industry (United States) and, with a market value of $210.52B, is number 9 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $29.44B (up 2.4% year on year) and earnings of $8.51B (up 1,672.9%).
- For fiscal 2026, analysts expect on average revenue of $31.27B (up 6.2%) and adjusted earnings per share of −$0.85.
Show more
- MEQIRI Score 58 out of 100 (Neutral): rank 303 of 714 in Healthcare, median 53.
- Our model puts fair value at $220.46, with the price 23% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 133.8% a year since 2020.
- High return on capitalReturn on invested capital 28.1% in fiscal 2025, Drug Manufacturers (General) median 13.4%.
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 70
Weaknesses
- Loss-makingLoss of $3.86B over the last 12 months.
- High debtDebt 2.02 times equity (latest quarter), Drug Manufacturers (General) median 1.2.Stability 61
Its standout strengths are momentum and technical analysis, while growth and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among the 100 largest stocks.
From 2016 to 2025, 4 in 100 such stocks fell 30% or more within a year, against a group average of 9 in 100.
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $169.59 and expensive above $314.95 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $180.64, at 7.8% it would be $280.37.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6.5% on the twelve months before. Revenue has grown strongly since 2006, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 79%, operating 40%, net 29%. Last 12 months: net −12%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 9 Feb 2027in 89 days
- Last reported
- 29 Oct 2026EPS reported $2.55 (expected $2.19)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 106.6% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.85−106.6%
- Revenue
- $31.27B+1.8%
- Earnings per share
- $10.10+1.2%
- Revenue
- $33.49B+2.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +0.5%2026 guidance raised: base business sales $29.8 billion to $30.1 billion (up $350 million at the midpoint), HIV growth 9% to 10% versus 8% before, total product sales $30.1 billion to $30.4 billion.
“Given the strong performance in the first half of the year, we now expect full year 2026 HIV sales to grow between 9% and 10% compared to 2025, up from our prior expectation of 8% and driven by continued strong growth in Biktarvy, Yeztugo and Descovy.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $50.93M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Cain Wettan Keeley MSale
6 Nov 2026, EVP Gen Counsel, Legal & Comp
- Shares
- 3,399
- Price
- $164.11
- Value
- $557,810
- O'Day Daniel PatrickSale
5 Nov 2026, Chairman & CEO
- Shares
- 9,810
- Price
- $175.17
- Value
- $1.72M
- O'Day Daniel PatrickSale
4 Nov 2026, Chairman & CEO
- Shares
- 102,619
- Price
- $175.16
- Value
- $17.98M
Show 21 more
- O'Day Daniel PatrickSale
2 Nov 2026, Chairman & CEO
- Shares
- 15,000
- Price
- $169.74
- Value
- $2.55M
- O'Day Daniel PatrickSale
30 Oct 2026, Chairman & CEO
- Shares
- 15,881
- Price
- $175.25
- Value
- $2.78M
- Dickinson Andrew DSale
15 Oct 2026, Chief Financial Officer
- Shares
- 3,000
- Price
- $156.22
- Value
- $468,660
- Mercier JohannaSale
15 Oct 2026, Chief Comm & Corp Aff Officer
- Shares
- 3,000
- Price
- $156.22
- Value
- $468,660
- O'Day Daniel PatrickSale
1 Oct 2026, Chairman & CEO
- Shares
- 15,000
- Price
- $147.90
- Value
- $2.22M
- Dickinson Andrew DSale
15 Sept 2026, Chief Financial Officer
- Shares
- 3,000
- Price
- $145.29
- Value
- $435,870
- Mercier JohannaSale
15 Sept 2026, Chief Comm & Corp Aff Officer
- Shares
- 3,000
- Price
- $144.22
- Value
- $432,646
- O'Day Daniel PatrickSale
1 Sept 2026, Chairman & CEO
- Shares
- 15,000
- Price
- $148.64
- Value
- $2.23M
- Welters AnthonySale
26 Aug 2026, Board
- Shares
- 18,000
- Price
- $148.62
- Value
- $2.68M
- Bluestone JeffreySale
20 Aug 2026, Board
- Shares
- 5,000
- Price
- $145.02
- Value
- $725,078
- Dickinson Andrew DSale
17 Aug 2026, Chief Financial Officer
- Shares
- 3,000
- Price
- $138.36
- Value
- $415,080
- Mercier JohannaSale
17 Aug 2026, Chief Comm & Corp Aff Officer
- Shares
- 28,000
- Price
- $137.64
- Value
- $3.85M
- O'Day Daniel PatrickSale
3 Aug 2026, Chairman & CEO
- Shares
- 15,000
- Price
- $130.31
- Value
- $1.95M
- Dickinson Andrew DSale
15 Jul 2026, Chief Financial Officer
- Shares
- 3,000
- Price
- $129.93
- Value
- $389,777
- Mercier JohannaSale
15 Jul 2026, Chief Comm & Corp Aff Officer
- Shares
- 3,000
- Price
- $129.92
- Value
- $389,758
- O'Day Daniel PatrickSale
1 Jul 2026, Chairman & CEO
- Shares
- 15,000
- Price
- $126.29
- Value
- $1.89M
- Mercier JohannaSale
15 Jun 2026, Chief Comm & Corp Aff Officer
- Shares
- 3,000
- Price
- $123.92
- Value
- $371,762
- Dickinson Andrew DSale
15 Jun 2026, Chief Financial Officer
- Shares
- 3,000
- Price
- $125.40
- Value
- $376,200
- O'Day Daniel PatrickSale
1 Jun 2026, Chairman & CEO
- Shares
- 15,000
- Price
- $131.46
- Value
- $1.97M
- Dickinson Andrew DSale
15 May 2026, Chief Financial Officer
- Shares
- 3,000
- Price
- $132.27
- Value
- $396,810
- Mercier JohannaSale
15 May 2026, Chief Comm & Corp Aff Officer
- Shares
- 28,000
- Price
- $131.29
- Value
- $3.68M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Gilead Sciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- MerckMRK $362.86B68
- NovartisNOVN.SW $302.09B76
- AstraZenecaAZN $287.66B73
- AmgenAMGN $253.21B77
- Novo NordiskNOVO-B.CO $178.97B79
- PfizerPFE $167.86B61
- Bristol-Myers SquibbBMY $128.59B71
- SanofiSAN.PA $115.46B67
ETFs that hold Gilead Sciences
Held by 165 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 9.19% | 0.35% | €1.21B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 3.15% | 0.15% | €3.27B |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 3.14% | 0.12% | €1.34B |
Show 5 more
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 3.10% | 0.15% | €592.11M |
| UBS Factor MSCI USA Quality Screened UCITS ETF USD disUBUT | 2.75% | 0.25% | €1.14B |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 2.68% | 0.18% | €837.43M |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 2.26% | 0.25% | €4.18B |
| Global X Genomics & Biotechnology UCITS ETFGN0M | 1.81% | 0.50% | €127.06M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 28 Aug 2026)
- Valuation signal Fairly valued since 11 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.